文献速递细菌感染、耐药与抗菌药物

肠杆菌科血流感染7天与14天抗生素疗程随机对照试验

Seven-versus 14-day course of antibiotics for the treatment of bloodstream infections by Enterobacterales: a randomized, controlled trial.
PubMed 文献 · Clin Microbiol Infect · 2021-09-09

一项随机对照试验纳入248例已获适当源控制的成人肠杆菌科血流感染患者,比较7天与14天抗生素疗程。意向性分析显示,随访结束时两组中位治疗天数分别为7天和14天(差值7,95%CI 7-7)。除发热复发外,临床结局均达到非劣效界值,DOOR/RADAR分析显示7天方案有77.7%的概率获得更优结果。

要点

  • 在适当源控制前提下,7天疗程可显著减少肠杆菌科血流感染患者的抗生素暴露。
  • 临床结局总体达到非劣效,但发热复发未完全排除,需关注但不必因此延长疗程。
  • 缩短疗程的获益超过少数发热复发的风险,支持临床采用7天方案。

核心结论

  • 7天疗程可减少肠杆菌科血流感染患者的抗生素暴露,同时临床结局与14天疗程相似。
  • 少数患者可能出现发热复发,但与最终结局无关,且被缩短疗程的获益所抵消。

研究设计与样本

  • 随机对照试验,纳入248例发生肠杆菌科血流感染且已适当源控制的成人患者。
  • 患者被分配至7天组(n=119)或14天组(n=129),治疗结束后随访28天,必要时可恢复治疗。

主要发现

  • 意向性分析中,随访结束时中位治疗天数分别为7天和14天(差值7,95%CI 7-7)。
  • 临床结局达到非劣效界值,但发热复发一项为-0.2%(95%CI -10.4至10.1)。
  • DOOR/RADAR分析显示7天方案有77.7%的概率获得优于14天治疗的结果。

关键数值与推荐

  • 主要终点优效界值为3天,临床结局非劣效界值为10%。
  • 发热复发差值-0.2%(95%CI -10.4至10.1)。

临床怎么用

  • 对已实现适当源控制的成人肠杆菌科血流感染,可考虑采用7天抗生素疗程以减少暴露。
  • 治疗结束后仍需随访,必要时可恢复治疗,尤其关注发热复发情况。

局限性

  • 发热复发在少数患者中不能排除,需在临床随访中关注。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To prove that 7-day courses of antibiotics for bloodstream infections caused by members of the Enterobacterales (eBSIs) allow a reduction in patients' exposure to antibiotics while achieving clinical outcomes similar to those of 14-day schemes. METHODS: A randomized trial was performed. Adult patients developing eBSI with appropriate source control were assigned to 7 or 14 days of treatment, and followed 28 days after treatment cessation; treatments could be resumed whenever necessary. The primary endpoint was days of treatment at the end of follow-up. Clinical outcomes included clinical cure, relapse of eBSI and relapse of fever. A superiority margin of 3 days was set for the primary endpoint, and a non-inferiority margin of 10% was set for clinical outcomes. Efficacy and safety were assessed together with a DOOR/RADAR (desirability of outcome ranking and response adjusted for duration of antibiotic risk) analysis. RESULTS: 248 patients were assigned to 7 (n = 119) or 14 (n = 129) days of treatment. In the intention-to-treat analysis, median days of treatment at the end of follow-up were 7 and 14 days (difference 7, 95%CI 7-7). The non-inferiority margin was also met for clinical outcomes, except for relapse of fever (-0.2%, 95%CI -10.4 to 10.1). The DOOR/RADAR showed that 7-day schemes had a 77.7% probability of achieving better results than 14-day treatments. CONCLUSIONS: 7-day schemes allowed a reduction in antibiotic exposure of patients with eBSI while achieving outcomes similar to those of 14-day schemes. The possibility of relapsing fever in a limited number of patients, without relevance to final outcomes, may not be excluded, but was overcome by the benefits of shortening treatments.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Molina J, Montero-Mateos E, Praena-Segovia J, et al. Seven-versus 14-day course of antibiotics for the treatment of bloodstream infections by Enterobacterales: a randomized, controlled trial. Clin Microbiol Infect. 2021. PMID: 34508886. doi:10.1016/j.cmi.2021.09.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。